Reducing ovarian fibrosis extends female reproductive lifespan

Anna Kriebs

DOI: https://doi.org/10.1038/s43587-022-00273-1

2022-08-04

Nature Aging

Abstract:Nature Aging, Published online: 03 August 2022; doi:10.1038/s43587-022-00273-1 Reducing ovarian fibrosis extends female reproductive lifespan

What problem does this paper attempt to address?

Female reproductive life span is extended by targeted removal of fibrotic collagen from the mouse ovary

Takashi Umehara,Yasmyn E. Winstanley,Eryk Andreas,Atsushi Morimoto,Elisha J. Williams,Kirsten M. Smith,John Carroll,Mark A. Febbraio,Masayuki Shimada,Darryl L. Russell,Rebecca L. Robker

DOI: https://doi.org/10.1126/sciadv.abn4564

IF: 13.6

2022-06-18

Science Advances

Abstract:The female ovary contains a finite number of oocytes, and their release at ovulation becomes sporadic and disordered with aging and with obesity, leading to loss of fertility. Understanding the molecular defects underpinning this pathology is essential as age of childbearing and obesity rates increase globally. We identify that fibrosis within the ovarian stromal compartment is an underlying mechanism responsible for impaired oocyte release, which is initiated by mitochondrial dysfunction leading to diminished bioenergetics, oxidative damage, inflammation, and collagen deposition. Furthermore, antifibrosis drugs (pirfenidone and BGP-15) eliminate fibrotic collagen and restore ovulation in reproductively old and obese mice, in association with dampened M2 macrophage polarization and up-regulated MMP13 protease. This is the first evidence that ovarian fibrosis is reversible and indicates that drugs targeting mitochondrial metabolism may be a viable therapeutic strategy for women with metabolic disorders or advancing age to maintain ovarian function and extend fertility.

multidisciplinary sciences
Systemic low-dose anti-fibrotic treatment attenuates ovarian aging in the mouse

Farners Amargant i Riera,Carol Vieira,Michele Pritchard,Francesca Duncan

DOI: https://doi.org/10.1101/2024.06.21.600035

2024-06-25

Abstract:The female reproductive system is one of the first to age in humans, resulting in infertility and endocrine disruptions. The aging ovary assumes a fibro-inflammatory milieu which negatively impacts gamete quantity and quality as well as ovulation. Here we tested whether the systemic delivery of anti-inflammatory (Etanercept) or anti-fibrotic (Pirfenidone) drugs attenuates ovarian aging in mice. We first evaluated the ability of these drugs to decrease the expression of fibro-inflammatory genes in primary ovarian stromal cells. Whereas Etanercept did not block Tnf expression in ovarian stromal cells, Pirfenidone significantly reduced Col1a1 expression. We then tested Pirfenidone in vivo where the drug was delivered systemically via mini-osmotic pumps for 6-weeks. Pirfenidone mitigated the age-dependent increase in ovarian fibrosis without impacting overall health parameters. Ovarian function was improved in Pirfenidone-treated mice as evidenced by increased follicle and corpora lutea number, AMH levels, and improved estrous cyclicity. Transcriptomic analysis revealed that Pirfenidone treatment resulted in an upregulation of reproductive function-related genes at 8.5 months and a downregulation of inflammatory genes at 12 months of age. These findings demonstrate that reducing the fibroinflammatory ovarian microenvironment improves ovarian function, thereby supporting modulating the ovarian environment as a therapeutic avenue to extend reproductive longevity.

Developmental Biology
Unraveling female reproductive senescence to enhance healthy longevity

Lu Dong,Daniel Boon Loong Teh,Brian Keith Kennedy,Zhongwei Huang

DOI: https://doi.org/10.1038/s41422-022-00718-7

IF: 44.1

2023-01-02

Cell Research

Abstract:In a society where women often want successful careers and equal opportunities to men, the early nature of ovarian aging often forces women to make difficult life choices between career and family development. Fertility in women begins to decline after the age of 37 years and it is rare for pregnancies to occur after 45. This reproductive decline in women is inevitable and culminates in menopause, which is a major driver of age-related diseases. In a world where biomedical advances are leading to modifiable biological outcomes, it is time to focus on mitigating female reproductive senescence to maintain fertility and preserve age-related hormonal functions, with the goal of providing increased life choices and enhancing healthspan. To date, reproductive longevity research remains an understudied field. More needs to be done to unravel the biology of the ovarian follicles, which are the functional units of reproductive lifespan and are comprised of cell types including the oocyte (female gamete) and a group of specialized supporting somatic cells. Biological attempts to maintain the quality and quantity of follicles in animal models through manipulating pathways involved in aging can potentially prolong female reproductive lifespan and healthspan. Here, we summarize the molecular events driving ovarian aging and menopause and the interventional strategies to offset these events. Developing solutions to female reproductive senescence will open doors to discover ways to enhance true healthy longevity for both men and women.

cell biology
Fsh/fshr/tgf-β1/smads signaling cascade mediates ovarian fibrosis resulting in ovarian aging

Yanye Zhang,Dan Zhang

DOI: https://doi.org/10.1016/j.fertnstert.2023.08.129

IF: 6.7

2023-01-01

Fertility and Sterility

Abstract:Whether progressively elevated FSH during physiological ovarian decay could be involved in ovarian aging via regulating ovarian fibrosis. We first established a mouse model of high serum FSH levels without dramatic decrease in estrogen via GnRHa and FSH injections instead of oophorectomy. Further, we blocked FSH action in mice with high FSH by anti-FSHβ antibodies (FSHAb) treatment. The mice serum levels of FSH, E2, and follicle numbers were measured in each group. Ovarian fibrosis was assessed by Masson trichrome and Sirius red staining, transmission electron microscopy, and expressions of several fibrotic molecules. Primary mouse ovarian fibroblasts (MOFs) were isolated and purified from the ovaries of 3-week-old mice and the FSHR expression was confirmed by Western blot. Fshr was knocked down in MOFs by siRNA. RNA-seq was used to analyze the transcriptomes of mouse ovaries from those treated with FSHAb or IgG. And the CUT&Tag assay was conducted on the FSH-treated MOFs. Differences among each group were compared using a two-tailed unpaired t-test for two groups and a one-way analysis of variance for multiple groups. p < 0.05 was considered statistically significant. We found that high FSH induced a significant decline in ovarian follicle numbers, especially the primordial and primary follicles, regardless of whether E2 was lower or normal. We also observed accelerated ovarian fibrosis in mice with higher FSH. Anti-FSHβ antibodies treatment could significantly reduce ovarian fibrosis in mice with high FSH and increase the primordial and primary follicles numbers. The functional FSHR is expressed in MOFs. FSH could significantly induce the expression of fibrotic molecules (COL3A1, COL5A2, COL1A1, and COL1A2) in MOFs in a dose and time-dependent manner, which could be reversed by Fshr knockdown. Mechanistically, GO and KEGG analysis indicated downregulation of TGFβ signaling in the ovaries of mice treated with FSHAb, compared with those treated with IgG. In vitro, FSH treatment could activate TGFβ1 signaling, as shown by increased phosphorylation of Smad2/3 and Smad4, and increased nucleus translocation of the Smads complex in MOFs. Fshr knockdown or SB431542, a TGF-β receptor 1 inhibitor, could suppress FSH-induced Smads complex activation. Further, the CUT&Tag assay showed that FSH significantly increased the direct binding of p-Smad3 to the genomic regions of Col1a1, Col1a2, Col3a1, and Col5a2. We proved that high serum FSH levels promoted ovarian fibrosis through FSHR/TGF-β1/Smads signaling pathway, leading to decreased ovarian reserve. Blocking FSH, silencing Fshr, or inhibiting the TGF-β1 pathway could effectively reduce ovarian fibrosis and restore the number of follicles.
Follicle-Stimulating Hormone Alleviates Ovarian Aging by Modulating Mitophagy- and Glycophagy-Based Energy Metabolism in Hens

Juan Dong,Changquan Guo,Zhaoyu Yang,Yangyang Wu,Caiqiao Zhang

DOI: https://doi.org/10.3390/cells11203270

IF: 6

2022-01-01

Cells

Abstract:As a predominant hormone in the reproductive axis, follicle-stimulating hormone (FSH) is known as the primary surviving factor for follicular growth. In this study, the alleviating effect of FSH on aging chicken granulosa cells (GCs) was investigated. Results showed that FSH activated mitophagy and relieved mitochondrial edema in D-gal-induced senescent GCs, which was evidenced by an increased number of mitophagosomes as well as increased mitochondria-light chain 3 (LC3) colocalization. Mitophagy activation was accompanied by the activation of the AMP-activated protein kinase (AMPK) signaling pathway. Furthermore, upregulated glycophagy was demonstrated by an increased interaction of starch-binding domain protein 1 (STBD1) with GABA type A receptor-associated protein-like 1 (GABARAPL1) in D-gal-induced senescent GCs. FSH treatment further promoted glycophagy, accompanied by PI3K/AKT activation. PI3K inhibitor LY294002 and AKT inhibitor GSK690693 attenuated the effect of FSH on glycophagy and glycolysis. The inhibition of FSH-mediated autophagy attenuated the protective effect of FSH on naturally aging GC proliferation and glycolysis. The simultaneous blockage of PI3K/AKT and AMPK signaling also abolished the positive effect of FSH on naturally senescent ovarian energy regulation. These data reveal that FSH prevents chicken ovarian aging by modulating glycophagy- and mitophagy-based energy metabolism through the PI3K/AKT and AMPK pathways.
Female germline stem cells: aging and anti-aging

Wenli Hong,Baofeng Wang,Yasha Zhu,Jun’e Wu,Li Qiu,Shuyi Ling,Ziqiong Zhou,Yuqing Dai,Zhisheng Zhong,Yuehui Zheng

DOI: https://doi.org/10.1186/s13048-022-01011-2

2022-07-05

Journal of Ovarian Research

Abstract:The delay of ovarian aging and the fertility preservation of cancer patients are the eternal themes in the field of reproductive medicine. Acting as the pacemaker of female physiological aging, ovary is also considered as the principle player of cancer, cardiovascular diseases, cerebrovascular diseases, neurodegenerative diseases and etc. However, its aging mechanism and preventive measures are still unclear. Some researchers attempt to activate endogenous ovarian female germline stem cells (FGSCs) to restore ovarian function, as the most promising approach. FGSCs are stem cells in the adult ovaries that can be infinitely self-renewing and have the potential of committed differention. This review aims to elucidate FGSCs aging mechanism from multiple perspectives such as niches, immune disorder, chronic inflammation and oxidative stress. Therefore, the rebuilding nichs of FGSCs, regulation of immune dysfunction, anti-inflammation and oxidative stress remission are expected to restore or replenish FGSCs, ultimately to delay ovarian aging.

reproductive biology
Ovarian aging: mechanisms and intervention strategies

Zhengmao Zhu,Wanxue Xu,Lin Liu

DOI: https://doi.org/10.1515/mr-2022-0031

2022-11-22

Abstract:Ovarian reserve is essential for fertility and influences healthy aging in women. Advanced maternal age correlates with the progressive loss of both the quantity and quality of oocytes. The molecular mechanisms and various contributing factors underlying ovarian aging have been uncovered. In this review, we highlight some of critical factors that impact oocyte quantity and quality during aging. Germ cell and follicle reserve at birth determines reproductive lifespan and timing the menopause in female mammals. Accelerated diminishing ovarian reserve leads to premature ovarian aging or insufficiency. Poor oocyte quality with increasing age could result from chromosomal cohesion deterioration and misaligned chromosomes, telomere shortening, DNA damage and associated genetic mutations, oxidative stress, mitochondrial dysfunction and epigenetic alteration. We also discuss the intervention strategies to delay ovarian aging. Both the efficacy of senotherapies by antioxidants against reproductive aging and mitochondrial therapy are discussed. Functional oocytes and ovarioids could be rejuvenated from pluripotent stem cells or somatic cells. We propose directions for future interventions. As couples increasingly begin delaying parenthood in life worldwide, understanding the molecular mechanisms during female reproductive aging and potential intervention strategies could benefit women in making earlier choices about their reproductive health.
P-474 Development of a preclinical screening pipeline to test the efficacy of anti-fibrotic and anti-inflammatory drugs on ovarian aging

F. Duncan,F. Amargant

DOI: https://doi.org/10.1093/humrep/deac107.446

IF: 6.1

2022-06-29

Human Reproduction

Abstract:Can either systemic or targeted ovarian delivery of anti-inflammatory (Etanercept) or anti-fibrotic (Pirfenidone) drugs have a therapeutic effect on ovarian aging in mice? We have established an in vitro and in vivo pre-clinical pipeline in the mouse to evaluate the effect of drugs on ovarian aging. The female reproductive system is the first to age in humans, beginning when women reach their mid-thirties. Reproductive aging results in infertility and hormonal perturbations which have general health consequences. Most research on reproductive aging has focused on the age-associated reduction in oocyte quantity and quality. However, our lab discovered that the ovarian microenvironment (stroma) in which the gamete develops changes with age. Specifically, a pro-inflammatory milieu develops with a significant increase in pro-inflammatory cytokine production including interleukin-6. Concurrently, collagen I/III accumulates resulting in fibrosis. This fibrotic and inflammatory milieu likely impacts oocyte quality contributing to reproductive aging. Etanercept was selected as an anti-inflammatory drug because it binds and inhibits TNF-a/b. Pirfenidone was selected as anti-fibrotic drug because it targets collagen I/III and TGF-b1. In vitro studies were performed using tissue explant-cultures to evaluate the toxicity of the drugs on the ovary. In vivo studies were based on the delivery of these drugs either systemically or targeted to the ovary using mini-osmotic pumps to evaluate the impact of these drugs on ovarian aging. In vitro studies: Ovaries from 7-month (N = 6) and 14-month (N = 6) old CD1 mice were isolated, dissected into equal pieces, and incubated in Pirfenidone (0.05, 0.5, 5mM), Etanercept (1, 10, 100g/ml), or the drug diluent (controls). After 24h the explants were collected and tissue architecture (H&E), collagen content (Picrosirius red/PSR), and cell death (Caspase-3) was analyzed using histochemical approaches. In vivo studies: Alzet mini-osmotic pumps were implanted subcutaneously and 2-delivery approaches tested: systemic (N = 2) and ovarian-targeted(N = 2). We first evaluated the toxicity of Etanercept and Pirfenidone on the ovary using our in vitro system. H&E staining revealed that the structure of the Etanercept and Pirfenidone-treated ovaries were similar to controls. The collagen content was also not significantly different in all groups (p > 0.05, One-way ANOVA, Tukey’s test). However, 5mM Pirfenidone and 10 and 100g/ml Etanercept treatments resulted in a trend of decreased collagen relative to the control ovaries. Cleaved Caspase-3 fluorescent intensity/area was also similar in all conditions (p > 0.05, One-way ANOVA, Tukey’s test). Therefore, our in vitro studies show that Pirfenidone and Etanercept are not toxic demonstrating the potential use of these drugs in the ovary. Next, we tested the use of these drugs in vivo with osmotic pumps in 7-month old mice, when ovarian fibrosis is first observed. As a proof-of-concept, the pump was filled with Alcian Blue (dye). Pumps were implanted subcutaneously for systemic and targeted delivery. For the targeted delivery, the pump was connected to a catheter which was inserted underneath the bursa. The pumps were well tolerated by the mice. Two weeks after surgery the catheters were still attached to the ovaries and none of the ovaries showed structural abnormalities when analyzed with H&E. We have established a preclinical pipeline to screen the potential of drugs to extend reproductive longevity. Studies are ongoing to determine the efficacy of Pirfenidone and Etanercept in delaying fibrosis and inflammation in the ovary to improve reproductive outcomes. Experiments to determine the side effects of these drugs are required. Our in vitro studies show that Pirfenidone and Etanercept are not toxic to the ovary suggesting a therapeutic potential of anti-fibrotic and anti-inflammatory drugs in delaying reproductive aging. Our in vivo preclinical pipeline represents a novel system to evaluate the therapeutic effect of these and other drugs on ovarian aging. N/A

Biology,Medicine
Resveratrol alleviates inflammation and ER stress through SIRT1/NRF2 to delay ovarian aging in a short-lived fish.

Xiaowen Li,Guorong Li,Hongyan Zhu,Mengxue Qiao,Xiaowen Sun

DOI: https://doi.org/10.1093/gerona/glad009

2023-01-11

Abstract:Aging is a complex process in which the structure and function of various tissues and organs gradually decline with age, and ovarian aging affects the reproductive capacity of females and induces age-related diseases. Resveratrol, a natural polyphenol compound, extends the lifespan and has a protective effect on ovaries of vertebrates. However, the effects and underlying mechanisms of resveratrol delaying ovarian aging are unclear. In the present study, using an annual fish N. guentheri, we demonstrated that senescence-associated-beta-galactosidase (SA-β-gal) activity and lipofuscin accumulation increased with age in the ovaries, and resveratrol reversed this phenomenon. Resveratrol increased proliferating cell nuclear antigen (PCNA) expression and the oocyte proportions of primary growth stage, cortical alveolus stage and vitellogenesis stage, and decreased the number of atretic follicles in the ovaries of 6-, 9-, 12-month-old fish. Moreover, the expression of SIRT1 and NRF2 decreased and the levels of NF-κB, pro-inflammatory cytokines IL-1β, TNF-α and IL-8 and endoplasmic reticulum (ER) stress markers GRP78 and CHOP increased with aging, while resveratrol up-regulated SIRT1 and NRF2 expression and down-regulated NF-κB, IL-1β, TNF-α, IL-8, GRP78 and CHOP levels in the ovaries of 6-, 9-month-old fish. In HEK293T cells, knockdown SIRT1 decreased NRF2 and increased NF-κB p65, pro-inflammatory cytokines (IL-1β and TNF-α) and ER stress marker GRP78 expression markedly. Silencing SIRT1 and then treating the cells with resveratrol significantly reversed the phenomenon. Collectively, resveratrol might activate SIRT1/NRF2 to reduce inflammation and ER stress, and finally delay ovarian aging in a short-lived fish. This study highlights the protective effect and mechanism of resveratrol on ovarian aging.

Medicine,Biology,Environmental Science
Cell-Free Fat Extract Improves Ovarian Function and Fertility in Mice With Advanced Age

Mengyu Liu,Wenzhu Li,Xiaowei Zhou,Mingjuan Zhou,Wenjie Zhang,Qiang Liu,Aijun Zhang,Bufang Xu

DOI: https://doi.org/10.3389/fendo.2022.912648

IF: 6.055

2022-06-16

Frontiers in Endocrinology

Abstract:The reduction in the quantity and quality of oocytes is the major factor affecting fertility in women with advanced age, who tend to experience delayed childbearing and declined fertility rate. However, effective therapeutic strategies to combat this decrease in ovarian function are lacking in clinical practice. Thus, identifying a new method to rescue ovarian function and improve reproduction in natural age-related decline in fertility is necessary. Cell-free fat extract (CEFFE) has been verified to possess diverse active proteins exerting anti-aging and proliferation-promoting effects. Nonetheless, whether CEFFE can rescue the decline in aged-related ovarian function and improve the fertility of females with advanced age remains unclear. In this study, a natural aging mouse model, exhibiting similarities to the physiological changes of ovarian senescence, was used to observe the anti-aging effect of CEFFE on ovarian functions. We found that CEFFE, injected via the veins, could recover the levels of the sex hormone, increase angiogenesis and the number of growth follicles in the natural aging mice model. Moreover, CEFFE promoted the development of embryos and increased the litter size of aged mice. Transcriptome analysis of the aged mouse ovaries revealed that CEFFE treatment upregulated the expression of genes involved in the repair of DNA damage. And both in vivo and in vitro experiment proved that CEFFE improved the function of granulosa cells, including promoting proliferation, alleviating senescence, and rescuing DNA damage in aged granulosa cells. Collectively, our study implied that CEFFE improved the ovarian function and fertility of naturally aging mice by ameliorating the overall microenvironment of ovary, which provided a theoretical basis for new anti-aging therapeutic strategies for cell-free therapy in ovaries.

endocrinology & metabolism
Mitochondria in Ovarian Aging and Reproductive Longevity

Jasmine L Chiang,Pallavi Shukla,Kelly Pagidas,Noha S Ahmed,Srinivasu Karri,Deidre D Gunn,William W Hurd,Keshav K Singh,Jasmine L. Chiang,Noha S. Ahmed,Deidre D. Gunn,William W. Hurd,Keshav K. Singh

DOI: https://doi.org/10.1016/j.arr.2020.101168

IF: 11.788

2020-11-01

Ageing Research Reviews

Abstract:Mitochondrial dysfunction is one of the hallmarks of aging. Consistently mitochondrial DNA (mtDNA) copy number and function decline with age in various tissues. There is increasing evidence to support that mitochondrial dysfunction drives ovarian aging. A decreased mtDNA copy number is also reported during ovarian aging. However, the mitochondrial mechanisms contributing to ovarian aging and infertility are not fully understood. Additionally, investigations into mitochondrial therapies to rejuvenate oocyte quality, select viable embryos and improve mitochondrial function may help enhance fertility or extend reproductive longevity in the future. These therapies include the use of mitochondrial replacement techniques, quantification of mtDNA copy number, and various pharmacologic and lifestyle measures. This review aims to describe the key evidence and current knowledge of the role of mitochondria in ovarian aging and identify the emerging potential options for therapy to extend reproductive longevity and improve fertility.

cell biology,geriatrics & gerontology,gerontology
The microbiota extends the reproductive lifespan by safeguarding the ovarian reserve

Sarah K Munyoki,Julie P Goff,Amanda Reshke,Erin Wilderoter,Nyasha Mafarachisi,Antonija Kolobaric,Yi Sheng,Steven Mullett,Gabrielle King,Jacob DeSchepper,Richard Bookser,Carlos A Castro,Stacy Gelhaus,Mayara Grizotte-Lake,Kathleen E Morrison,Anthony J Zeleznik,Timothy W Hand,Miguel Brieno-Enriquez,Eldin Jasarevic

DOI: https://doi.org/10.1101/2024.09.13.612929

2024-09-15

Abstract:Infertility is a devastating condition affecting one in six people globally. In many cases, the underlying causes are unknown. Emerging evidence suggests that the microbiota influences reproduction, yet the mechanistic link between the microbiota, ovarian function, and length of the fertile lifespan remain unexplored. Here we report that the microbiota controls the length of the reproductive lifespan by maintaining the primordial follicle pool, a process mediated by microbiota-derived short chain fatty acids modulating gene regulatory networks crucial for the survival of the ovarian reserve. Dietary perturbation of the microbiota during a critical developmental window is sufficient to diminish the ovarian reserve, reduce oocyte retrieval, and impair preimplantation embryo viability, mirroring challenges in human fertility treatments. Targeted interventions to restore microbiota improve assisted reproductive outcomes, particularly when implemented early. These findings reveal a novel contribution of host-microbe interactions in mammalian reproduction and demonstrate that the microbiota impacts ovarian function and fertility.

Developmental Biology
P-591 Follicular Fluid-Derived Exosomes Rejuvenate Ovarian Aging Through Mir-320A-3p-mediated FOXQ1 Inhibition

Liu Y,Liying Yan,M Xixiang,Wenpei Xiang

DOI: https://doi.org/10.1093/humrep/dead093.921

IF: 6.1

2023-01-01

Human Reproduction

Abstract:Study question Dose the follicular fluid-derived exosomes rejuvenate ovarian aging? Summary answer Follicular fluid-derived exosomes efficiently rescued ovarian function in aged mice, which was achieved via transfer of miR-320-3p to granulosa cells and subsequent Foxq1 inhibition. What is known already The ovary enters the malfunctional aging phase earlier and faster than other organs and systems. Ovarian aging is mainly characterized by a progressive decline in oocyte quantity and quality, which ultimately leads to female infertility. Various therapies have been established to cope with age-related ovarian dysfunction, among which exosome-based therapy has been considered a promising strategy that can benefit ovarian functions via multiple pathways. Study design, size, duration Ovarian granulosa cells of young C57BL/6J mice (6-8 w) and old C57BL/6J mice (40 w) were cultured in vitro. The follicular fluid exosomes of young mice and the same amount of PBS were respectively injected into the ovarian sac of old mice. Participants/materials, setting, methods Cell proliferation and apoptosis were detected by CCK8, flow cytometry and Western Blot. Mitochondrial function was assessed by measuring mitochondrial membrane potential, ATP levels, mtDNA copy numbers. The number of ovarian follicles were observed by HE staining. Senescence and telomere related gene expression levels were detected by RT-qPCR. 2-cell rates and blastocyst formation rates were observed after in vitro fertilization. The model mice were directly cooped up to observe the pregnat and litter sizes. Main results and the role of chance The follicular fluid exosomes from young mice can promote the proliferation of ovarian granulosa cells from old mice and improve mitochondrial function. When the follicular fluid exosomes from young mice were injected into the ovarian sac of old mice, the number of primordial and growing follicles in the ovaries of old mice were increased and the developmental ability of oocytes was improved. Limitations, reasons for caution Findings in mouse. Wider implications of the findings This study suggests that young follicular fluid exosomes may be involved in ovarian senescence by transferring miR-320a-3p targeting FOXQ1 into ovarian granulosa cells of aged mice. Trial registration number no
The role of cellular senescence in ovarian aging

Jéssica D Hense,José V V Isola,Driele N Garcia,Larissa S Magalhães,Michal M Masternak,Michael B Stout,Augusto Schneider

DOI: https://doi.org/10.1038/s41514-024-00157-1

2024-07-20

Abstract:This review explores the relationship between ovarian aging and senescent cell accumulation, as well as the efficacy of senolytics to improve reproductive longevity. Reproductive longevity is determined by the age-associated decline in ovarian reserve, resulting in reduced fertility and eventually menopause. Cellular senescence is a state of permanent cell cycle arrest and resistance to apoptosis. Senescent cells accumulate in several tissues with advancing age, thereby promoting chronic inflammation and age-related diseases. Ovaries also appear to accumulate senescent cells with age, which might contribute to aging of the reproductive system and whole organism through SASP production. Importantly, senolytic drugs can eliminate senescent cells and may present a potential intervention to mitigate ovarian aging. Herein, we review the current literature related to the efficacy of senolytic drugs for extending the reproductive window in mice.
Ovarian tissue autotransplantation improves longevity in mice

Nikolai N Ruhliada

DOI: https://doi.org/10.3389/fphys.2024.1443494

2024-08-29

Abstract:In this study, we show the improvement in life longevity in an experimental mouse model after step-by-step autologous ovarian transplantation and compare its effects with exogenic transdermal estradiol usage. This has proven to be more efficient than "traditional" hormonal replacement therapy. Despite the high speed and effectiveness of estradiol replacement deficiency in blood by its oral or transdermal use, no significant increase in the life longevity of animals and possibly in women was noted. The function of the transplanted fragment is usually limited to 6-12 months. This is enough for oncofertility purposes, sometimes, but not for longevity improvement. We performed periodical tissue return (autologous transplantation), containing both the cortex and medulla in the experimental mouse model, which resulted in a statistically reliable improvement in longevity. Our experience indicates the important role of medullary ovarian factors in slowing the aging process in the body and increasing the life expectancy in the experiment. As shown, the transdermal estrogen supportive therapy for ovarian deficiency improves estrogen levels but causes much slower decreases in the follicle stimulating hormone (FSH) and luteinizing hormone (LH). Moreover, we attained the best longevity with step-by-step periodic ovarian autotransplantation, thus making "prosthetics" of ovarian function longer than it is preplanned physiologically [direct correlation between the levels of FSH and lifespan (r = 0.98)]. The experimental model we suggested could be projected to other mammals or humans as cortical transplantation provides the same results for reproduction restoration in mice and humans and even for hormone level normalization, but there is still a lack of information about anti-aging factors in the ovarian medulla and cortex. Hence, we consider that the most important factor for the anti-aging ovarian transplantation technology is to preserve and transfer both the medulla and cortex as parts of the whole ovary.
Can ovarian aging be delayed by pharmacological strategies?

Jinjin Zhang,Qian Chen,Dingfu Du,Tong Wu,Jingyi Wen,Meng Wu,Yan Zhang,Wei Yan,Su Zhou,Yan Li,Yan Jin,Aiyue Luo,Shixuan Wang

DOI: https://doi.org/10.18632/aging.101784

2019-01-23

Aging

Abstract:Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.
Investigating the Role of Ferroptosis-Related Genes in Ovarian Aging and the Potential for Nutritional Intervention

Pei-Hsuan Lin,Wan-Ping Su,Chia-Jung Li,Li-Te Lin,Jim Jinn-Chyuan Sheu,Zhi-Hong Wen,Jiin-Tsuey Cheng,Kuan-Hao Tsui

DOI: https://doi.org/10.3390/nu15112461

IF: 5.9

2023-05-26

Nutrients

Abstract:With advancing age, women experience irreversible deterioration in the quality of their oocytes, resulting in reduced fertility. To gain a deeper understanding of the influence of ferroptosis-related genes on ovarian aging, we employed a comprehensive approach encompassing spatial transcriptomics, single-cell RNA sequencing, human ovarian pathology, and clinical biopsy. This investigation revealed the intricate interactions between ferroptosis and cellular energy metabolism in aging germ cells, shedding light on the underlying mechanisms. Our study involved 75 patients with ovarian senescence insufficiency, and we utilized multi-histological predictions of ferroptosis-related genes. Following a two-month supplementation period with DHEA, Ubiquinol CoQ10, and Cleo-20 T3, we examined the changes in hub genes. Our results showed that TFRC, NCOA4, and SLC3A2 were significantly reduced and GPX4 was increased in the supplement group, confirming our prediction based on multi-omic analysis. Our hypothesis is that supplementation would enhance the mitochondrial tricarboxylic acid cycle (TCA) or electron transport chain (ETC), resulting in increased levels of the antioxidant enzyme GPX4, reduced lipid peroxide accumulation, and reduced ferroptosis. Overall, our results suggest that supplementation interventions have a notable positive impact on in vitro fertilization (IVF) outcomes in aging cells by improving metal ion and energy metabolism, thereby enhancing oocyte quality in older women.

nutrition & dietetics
Examining the Effects of Nutrient Supplementation on Metabolic Pathways via Mitochondrial Ferredoxin in Aging Ovaries

Chia-Chun Wu,Chia-Jung Li,Li-Te Lin,Zhi-Hong Wen,Jiin-Tsuey Cheng,Kuan-Hao Tsui

DOI: https://doi.org/10.3390/nu16101470

IF: 5.9

2024-05-13

Nutrients

Abstract:As women age, oocytes are susceptible to a myriad of dysfunctions, including mitochondrial dysfunction, impaired DNA repair mechanisms, epigenetic alterations, and metabolic disturbances, culminating in reduced fertility rates among older individuals. Ferredoxin (FDX) represents a highly conserved iron-sulfur (Fe-S) protein essential for electron transport across multiple metabolic pathways. Mammalian mitochondria house two distinct ferredoxins, FDX1 and FDX2, which share structural similarities and yet perform unique functions. In our investigation into the regulatory mechanisms governing ovarian aging, we employed a comprehensive multi-omics analysis approach, integrating spatial transcriptomics, single-cell RNA sequencing, human ovarian pathology, and clinical biopsy data. Previous studies have highlighted intricate interactions involving excessive lipid peroxide accumulation, redox-induced metal ion buildup, and alterations in cellular energy metabolism observed in aging cells. Through a multi-omics analysis, we observed a notable decline in the expression of the critical gene FDX1 as ovarian age progressed. This observation prompted speculation regarding FDX1's potential as a promising biomarker for ovarian aging. Following this, we initiated a clinical trial involving 70 patients with aging ovaries. These patients were administered oral nutritional supplements consisting of DHEA, ubiquinol CoQ10, and Cleo-20 T3 for a period of two months to evaluate alterations in energy metabolism regulated by FDX1. Our results demonstrated a significant elevation in FDX1 levels among participants receiving nutritional supplementation. We hypothesize that these nutrients potentiate mitochondrial tricarboxylic acid cycle (TCA) activity or electron transport chain (ETC) efficiency, thereby augmenting FDX1 expression, an essential electron carrier in metabolic pathways, while concurrently mitigating lipid peroxide accumulation and cellular apoptosis. In summary, our findings underscore the potential of nutritional intervention to enhance in vitro fertilization outcomes in senescent cells by bolstering electron transport proteins, thus optimizing energy metabolism and improving oocyte quality in aging women.
Ovarian fibrosis: molecular mechanisms and potential therapeutic targets

Mengqing Gu,Yibo Wang,Yang Yu

DOI: https://doi.org/10.1186/s13048-024-01448-7

2024-07-05

Abstract:Ovarian fibrosis, characterized by the excessive proliferation of ovarian fibroblasts and the accumulation of extracellular matrix (ECM), serves as one of the primary causes of ovarian dysfunction. Despite the critical role of ovarian fibrosis in maintaining the normal physiological function of the mammalian ovaries, research on this condition has been greatly underestimated, which leads to a lack of clinical treatment options for ovarian dysfunction caused by fibrosis. This review synthesizes recent research on the molecular mechanisms of ovarian fibrosis, encompassing TGF-β, extracellular matrix, inflammation, and other profibrotic factors contributing to abnormal ovarian fibrosis. Additionally, we summarize current treatment approaches for ovarian dysfunction targeting ovarian fibrosis, including antifibrotic drugs, stem cell transplantation, and exosomal therapies. The purpose of this review is to summarize the research progress on ovarian fibrosis and to propose potential therapeutic strategies targeting ovarian fibrosis for the treatment of ovarian dysfunction.

Reducing ovarian fibrosis extends female reproductive lifespan

Female reproductive life span is extended by targeted removal of fibrotic collagen from the mouse ovary

Systemic low-dose anti-fibrotic treatment attenuates ovarian aging in the mouse

Unraveling female reproductive senescence to enhance healthy longevity

Fsh/fshr/tgf-β1/smads signaling cascade mediates ovarian fibrosis resulting in ovarian aging

Follicle-Stimulating Hormone Alleviates Ovarian Aging by Modulating Mitophagy- and Glycophagy-Based Energy Metabolism in Hens

Female germline stem cells: aging and anti-aging

Ovarian aging: mechanisms and intervention strategies

P-474 Development of a preclinical screening pipeline to test the efficacy of anti-fibrotic and anti-inflammatory drugs on ovarian aging

Resveratrol alleviates inflammation and ER stress through SIRT1/NRF2 to delay ovarian aging in a short-lived fish.

Cell-Free Fat Extract Improves Ovarian Function and Fertility in Mice With Advanced Age

Mitochondria in Ovarian Aging and Reproductive Longevity

The microbiota extends the reproductive lifespan by safeguarding the ovarian reserve

P-591 Follicular Fluid-Derived Exosomes Rejuvenate Ovarian Aging Through Mir-320A-3p-mediated FOXQ1 Inhibition

The role of cellular senescence in ovarian aging

Ovarian tissue autotransplantation improves longevity in mice

Can ovarian aging be delayed by pharmacological strategies?

Investigating the Role of Ferroptosis-Related Genes in Ovarian Aging and the Potential for Nutritional Intervention

Examining the Effects of Nutrient Supplementation on Metabolic Pathways via Mitochondrial Ferredoxin in Aging Ovaries

Ovarian fibrosis: molecular mechanisms and potential therapeutic targets